A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)

Trial Profile

A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms OSMO
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 13 May 2017 This trial has been completed in Spain.
    • 01 May 2017 Planned End Date changed from 9 Jun 2017 to 31 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top